Description: NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. The company's natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. NFL Biosciences SA was incorporated in 2006 and is based in Castelnau-le-Lez, France.
Home Page: www.nflbiosciences.com
199 Rue Hélène Boucher
Castelnau-le-Lez,
34170
France
Phone:
33 4 11 93 76 67
Officers
| Name | Title |
|---|---|
| Dr. Ignacio Faus M.B.A., Ph.D. | CEO & Chairman |
| Mr. Bruno Lafont M.B.A., M.Sc. | Co-Founder, COO & Director |
| Mr. Guillaume Audema | Chief Financial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.4615 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |